Today’s brief highlights the accelerating convergence of neoantigen vaccines with diverse immunomodulatory strategies, from T-cell engagers and CAR-engineered dendritic cells to CRISPR-edited TILs.trialtrialtrial
Key developments include early-stage trials in sarcoma, hepatocellular carcinoma, and glioblastoma, alongside preventive approaches for Lynch Syndrome, signaling a broadening clinical landscape beyond standard checkpoint inhibitor combinations.trialNatureNaturetrial
Shenzhen Geno-Immune Medical Institute is enrolling by invitation for a Phase 1 trial of an immunomodulatory dendritic cell (DC) vaccine in brain cancer, including glioblastoma and DIPG. The vaccine uses autologous DCs pulsed with genetically modified tumor cells or neoantigens to induce T cell responses linked to improved survival.
Sun Yat-sen University is recruiting for a Phase 1 trial of SarcVac, a tumor neoantigen vaccine combined with PD-1 antibodies and/or tumor-specific lymphocytes in advanced sarcoma. The study aims to evaluate safety, tolerability, and preliminary efficacy, specifically testing for dose dependency in patients who have failed first-line treatment.
Relevant work from earlier we're still surfacing — not today's news.